Skip to main content
Premium Trial:

Request an Annual Quote

With Revenues and Losses Up, Luminex Sets Date for Report on Corporate Assessment

NEW YORK, Oct. 21 (GenomeWeb News) - Luminex today reported an increase in third-quarter revenue and widened net loss.


The company also said it plans to release results of a strategic assessment of the business on Dec. 8.


"We are working hard to create a focused business, and one better suited to generate long-term shareholder value," Patrick Balthrop, president and CEO, said in a statement.


Revenue for the three months ended Sept. 30 increased to $8.4 million from $7.1 million year over year. The Austin, Texas-based molecular biology tools company recorded $4.3 million of revenue from the sale of 177 Luminex systems and $2.1 million from consumables.


R&D spending also increased, to $900,000 in the third quarter from $700,000 in the year-ago period.


Net loss widened to $1.2 million for the period, or $.04 per share, from $800,000, or $.03 per share, year over year.


Luminex said it had around $36.3 million in cash and equivalents.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.